Skip to content

The effect of bupropion on impotence in female MS patients

Efficacy and safety evaluation of bupropion on sexual dysfunction in female patients with multiple sclerosis - a double blind randomized clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140105016087N2
Enrollment
64
Registered
2021-04-23
Start date
2021-04-22
Completion date
Unknown
Last updated
2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Multiple Sclerosis. Condition 2: Sexual dysfunction. Multiple sclerosis Sexual dysfunction not due to a substance or known physiological condition

Interventions

Intervention 1: Intervention group:. Intervention 2: Control group:.

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adult women over 18 years The duration of MS is more than six months Having sexual activity in the last six months Not known to have an acute mental disorder Husband monogamy

Exclusion criteria

Exclusion criteria: Moderate to severe depression with HADS questionnaire (score 11 and above) Consumption of silicotropic drugs and benzodiazepines and SSRIs during the study Known for acute mental disorder Pregnancy or breastfeeding Peripheral problems of the genitourinary system lead to sexual dysfunction Facing severe crises such as the death of loved ones during the last six months Withdrawal from study and incomplete answers to the questionnaires so that more than 20% of the questions in each questionnaire are unanswered. History of seizures History of bulimia and anorexia

Design outcomes

Primary

MeasureTime frame
Intimacy and sexual activity in MSISQ 19 questionnaire. Timepoint: The beginning of the study, the sixth week and the twelfth week. Method of measurement: MSISQ 19 questionnaire.;Percentage of people with a depression score of less than 11 on the HADS questionnaire. Timepoint: The beginning of the study. Method of measurement: HADS questionnaire.

Secondary

MeasureTime frame
Multiple Sclerosis Quality Of Life. Timepoint: The beginning of the study-End of study. Method of measurement: (MSQOL-54).;Fatigue. Timepoint: The beginning of the study. Method of measurement: The Multidimensional Fatigue Inventory.;Sphincter disorders. Timepoint: The beginning of the study. Method of measurement: Sphincter Disorder Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mohammad Baghbanian

Mazandaran University of Medical Sciences

sm.baghbanian@mazums.ac.ir+98 11 3334 3348

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026